A 23-year-old woman comes to the outpatient psychiatric clinic for a follow-up appointment. Five months ago, she experienced the sudden onset of auditory hallucinations and persecutory delusions, believing that her university professors were conspiring to harm her. These symptoms began abruptly three days after she was involved in a severe motor vehicle collision. She was hospitalized and started on oral aripiprazole. Her psychotic symptoms completely resolved 3 weeks after they initially began. She was subsequently discharged and has been taking aripiprazole daily. She has had no recurrence of symptoms for the past 4 months, and her academic and social functioning have returned entirely to their premorbid baseline. She is bothered by mild weight gain and asks how much longer she must continue taking the medication. What is the most appropriate next step in the management of this patient's pharmacotherapy?
- Taper and discontinue the medication over the next few weeksCevap
- BContinue the medication for an additional 6 months
- CContinue the medication for an additional 1 to 2 years
- DContinue the medication indefinitely
- ECross-taper to an antipsychotic with a lower metabolic risk profile